Zhejiang Hisun Pharmaceutical
48 Waisha Road, Taizhou, Zhejiang Province, 318000, China
Overview
HISUN is one of the local leading pharmaceutical companies in China. It was founded in 1956; And this year would be their 60th anniversary. Over past 59 years, their company has always had positive revenue since it was established. HISUN was publicly shared in 2000 in Shanghai Stock Exchange. They are the largest antibiotics, anticancer drugs production supplier. They provide diverse products and services. Their research channels cover many indications extensively: like anticancer, cardiovascular, anti-infective, anti-parasitics, immunosuppressant, etc. With the respect to annual revenue, R&D expenditure as well as its Social Record, HISUN is definitely top 10 among the 7000 local Chinese Pharma. They believe innovation launches the best treatment for healthcare.
- Total investments
- 1
- Lead investments
- 1
- Investments · 12mo
- 0
- Active investors
- 0
Sector focus
- Biotechnology
- Health Care
- Pharmaceutical
Investment portfolio
- Sagent Pharmaceuticals
Led · Series B · Apr 2010
Sagent Pharmaceuticals, based in Schaumburg, Illinois, develops, manufactures, sources and markets pharmaceutical injectable products. The company participates across development, manufacturing, sourcing and commercial activities for injectable drugs. It completed a strategic Series B financing totaling $40M in two tranches—$10M from Zhejiang Hisun Pharmaceutical Co. Ltd. and $30M from an undisclosed China-focused private equity fund. To date, including this financing, Sagent has raised $153M in equity capital. Management, led by CEO, founder and chairman Jeffrey M. Yordon, says the investments will enrich strategic partnerships and extend access to additional products and facilities. The financing is expected to provide expanded access to Hisun's portfolio of active pharmaceutical ingredients and finished injectable product capabilities and to extend Sagent's reach into the Chinese injectable marketplace.
Team
No current team members are available.